Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
| Revenue (TTM) | $56.58B |
| Gross Profit (TTM) | $42.75B |
| EBITDA | $22.92B |
| Operating Margin | 30.50% |
| Return on Equity | 34.90% |
| Return on Assets | 10.50% |
| Revenue/Share (TTM) | $29.40 |
| Book Value | $20.18 |
| Price-to-Book | 7.70 |
| Price-to-Sales (TTM) | 5.30 |
| EV/Revenue | 5.92 |
| EV/EBITDA | 14.95 |
| Quarterly Earnings Growth (YoY) | -9.30% |
| Quarterly Revenue Growth (YoY) | -0.70% |
| Shares Outstanding | $1.91B |
| Float | $1.81B |
| % Insiders | 0.00% |
| % Institutions | 7.68% |
Volatility is currently expanding
Markets are being tested again. The AI trade has spent the past several weeks under real pressure, with memory, semiconductor, and neocloud names selling off hard after an extraordinary first half.
Novartis continues to favor in-licensing and bolt-on acquisitions. The Myricx Bio acquisition expands Novartis' ADC pipeline with novel NMTi payloads, but commercial impact is several years away. Avidity's del-brax and Ionis's pelacarsen, both late-stage assets, offer multibillion-dollar peak sales potential with pivotal data expected in the second half of the year.
NVS plans to acquire Myricx Bio for up to $1.5 billion, adding novel ADC technology to expand its oncology pipeline and tumor targets.
The deal for the privately held U.K.-based biotechnology firm will help bolster Novartis's oncology capabilities.
Swiss drugmaker Novartis said on Monday it had agreed to pay up to $1.5 billion for U.K.-based biotechnology firm Myricx Bio in a deal expected to close in the second half of 2026.
Novartis wins EC approval for Itvisma, the first gene replacement therapy for a broad SMA population, expanding treatment options from newborns to adults.
The first half of the year is over, and it may surprise some investors that European stocks are nearly at parity with U.S. stocks. The tale of the tape as of June 30 tells the story:
Antares Therapeutics said on Wednesday it entered a collaboration with Novartis that could be worth up to about $1.9 billion, aiming to develop therapies for historically hard-to-drug cancer targets.
BOSTON--(BUSINESS WIRE)--Antares Therapeutics, Inc. (“Antares”), a biotechnology company developing first-in-class precision medicines for cancer and other serious diseases, today announced a strategic collaboration with Novartis to discover, develop and commercialize small molecule therapies against promising but historically undruggable oncology targets. The agreement underscores the productivity and breadth of Antares' discovery capabilities, which have repeatedly delivered development candi.
The biotech sector's fundamentals are shifting rapidly-and the smartest money on Wall Street is already quietly rotating into the sector.
